Gossamer Bio
Clinical‑stage biopharma Gossamer Bio (San Diego) is advancing seralutinib to Phase 3 for pulmonary arterial hypertension, leveraging an inhaled PDGFR inhibitor platform and a partnership with Pulmokine for GB002 commercialization.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 144
- HQ: San Diego
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.